USPTO Further Clarifies Arthrex's Director Rehearing Process
The U.S. Patent and Trademark Office won't let parties requesting director review of Patent Trial and Appeal Board decisions under Arthrex present new arguments or evidence, according to additional guidance released by the agency on...To view the full article, register now.
Already a subscriber? Click here to view full article